

Curriculum Vitae

Personal information Consuelo Pedrós

Work experience

1. Employer: Consorcio Hospital General Universitario de Valencia
 - Start date: Dec2018
 - End date: Present
 - Position: Clinical Pharmacologist
 - Activities: Drug selection and drug policy. Methodological support to clinical research. Ethical and methodological assessment of research projects. Information on Drugs and Therapeutics. Research on pharmacovigilance and pharmacoepidemiology.
 - Country: Spain
2. Employer: Bellvitge University Hospital. Clinical Pharmacology Service
 - Start date: Aug2007
 - End date: Nov2018
 - Position: Clinical pharmacologist
 - Activities: Adverse drug reaction monitoring programme. Research on pharmacovigilance and pharmacoepidemiology. Pharmacovigilance in clinical trials. Information on Drugs and Therapeutics.
 - Country: Spain
3. Employer: Catalan Centre of the Spanish Pharmacovigilance System. Fundación Instituto Catalán de Farmacología
 - Start date: Jan2000
 - End date: Jul2007
 - Position: Pharmacovigilance Manager
 - Activities: Spontaneous reporting system. Adverse drug reaction monitoring programme. Research on pharmacovigilance and pharmacoepidemiology.
 - Country: Spain
4. Employer: Catalan Centre of the Spanish Pharmacovigilance System. Fundación Instituto Catalán de Farmacología
 - Start date: May1996
 - End date: Dec1999
 - Position: Pharmacovigilance Assistant and Researcher
 - Activities: Spontaneous reporting system. Research on pharmacovigilance and pharmacoepidemiology.
 - Country: Spain
5. Employer: Hospital Vall d'Hebron. Department of Clinical Pharmacology
 - Start date: Jan1992
 - End date: Dec1995
 - Position: Resident physician
 - Activities: Clinical practice on Internal Medicine, Emergencies, Cardiology, Intensive Care and Pneumology; Assistance on Pharmacovigilance, Therapeutic consultation, Drug utilization studies and Ethical and methodological review of clinical trials
 - Country: Spain

Education and training

1. Subject: Design and Analysis of Clinical Research
 - Start date: 2008
 - End date: 2009
 - Qualification: Master in Design and Analysis of Clinical Research
 - Organisation: University of Barcelona
 - Country: Spain
2. Subject: Clinical Pharmacology Specialist
 - Start date: Jan1992
 - End date: Dec1995
 - Qualification: Pharmacoepidemiology, Pharmacovigilance, Drug utilization studies, Ethical and methodological review of clinical trials, Therapeutic consultation
 - Organisation: Department of Clinical Pharmacology. Hospital Vall d'Hebron
 - Country: Spain
3. Subject: PhD degree
 - Start date: 1988
 - End date: 1999
 - Qualification: Research on basic and experimental pharmacology; research on pharmacology of potassium and calcium channels
 - Organisation: Faculty of Medicine, University of Valencia
 - Country: Spain
4. Subject: MD degree
 - Start date: 1982
 - End date: 1988
 - Qualification: MD degree
 - Organisation: Faculty of Medicine, University of Valencia
 - Country: Spain

Additional information

Publications

- Sancho-López A, Ruiz-Antorán B, Iglesias Hernangómez T, Ramírez-García A, Gómez Estevez I, Sanabria-Cabrera J, Llop Rius R, Pedrós C, Campodonico D, Jiménez-Jorge S, García Luque A, Costa Frossad França L, Montané E, Aldea-Perona A, Téllez Lara N, Bosch Ferrer M, Rodríguez Jiménez C, Bonilla-Toyos E, Sabin Muñoz J, Avendaño-Solá C, Blasco Quilez ML, on behalf of the REALHES-Study Group. The need for the closer monitoring of novel drugs in ms: a siponimod retrospective cohort study (Realhes Study). *J Clin Med* 2023;12:6471.
- Ruiz Antorán B, Sancho López A, Torres F, Moreno Torres V, de Pablo López I, García López P, Abad Santos F, Rosso Fernández CM, Aldea Perona A, Montané E, Aparicio Hernández RM, Llop Rius R, Pedrós C, Gijón P, Hernández Carballo C, Pedrosa Martínez MJ, Rodríguez Jiménez C, Prada Ramallal G, Cabrera García Lourdes, Aguilar García JA, Sanjuan Jimenez R, Ortiz Barraza EI, Sánchez Chica E, Fernández Cruz A on behalf of the TOCICOV study group. Combination of tocilizumab and steroids to improve mortality in patients with severe COVID 19 infection: a Spanish, multicenter, cohort study. *Infect Dis Ther* 2020;1:16.
- Pedrós C, Ávila A, Gómez Lumbreras A, Manríquez M, Morros R. Lactic acidosis associated with metformin in patients with moderate to severe chronic kidney disease: study protocol for a multicenter population-based case-control study using health databases. *BMC Nephrology* 2019;20:193.
- Pedrós C, Formiga F, Corbella X, Arnau JM. Adverse drug reactions leading to urgent hospital admission in an elderly population: prevalence and main features. *Eur J Clin Pharmacol* 2016;72:219-26.
- Vallano A, Castañeda PF, Quijada Manuitt MA, Simon PC, Pedrós C, Esterlich E, Arnau JM. Hospital doctors' views and concerns about pharmacovigilance. *J Pharmacovigilance* 2015;3:160.
- Pedrós C, Quintana B, Rebolledo M, Porta N, Vallano A, Arnau JM. Prevalence, risk factors and main features of adverse drug reactions leading to hospital admission. *Eur J Clin Pharmacol* 2014;70:361-7.
- Quijada Manuitt MA, Pedrós C, Quintana B, Arnau JM. Anticoncepción hormonal y tromboembolia venosa. *Med Clí (Barc)* 2013;142:418-9.
- Gómez Zorrilla S, Vallano Ferraz A, Pedrós C, Lemus M, Peña CV. Levetiracetam-induced drug reaction with eosinophilia and systemic symptoms syndrome. *Ann Pharmacother* 2012;46:e20.
- Vallano Ferraz A, Agustí Escasany A, Pedrós Cholvi C, Arnau de Bolós JM. Revisión sistemática de los estudios de evaluación del coste de las reacciones adversas a medicamentos. *Gac Sanit* 2012;26:277-83.
- Vallano A, Fernández Dueñas V, Pedrós C, Arnau JM, Ciruela F. An update on adenosine A2A receptors as drug target in Parkinson's disease. *CNS Neurol Disord Drug Targets* 2011;10:659-69.
- Pedrós Cholvi C, Arnau de Bolós JM. Hiponatremia y SIADH por medicamentos. *Rev Esp Geriatr Gerontol* 2010;45:229-31.
- Cereza G, Agustí A, Pedrós C, Vallano A, Aguilera C, Danés I, Vidal X, Arnau JM. Effect of an intervention on the features of adverse drug reactions spontaneously reported in a hospital. *Eur J Clin Pharmacol* 2010;66:937-45.
- Vallano A, Pedrós C, Agustí A, Cereza G, Danés I, Aguilera C, Arnau JM. Educational sessions in pharmacovigilance: What do the doctors think? *BMC Research Notes* 2010;3:311.
- Pedrós C, Vallano A, Cereza G, Mendoza Arán G, Agustí A, Aguilera C, Danés I, Vidal X. An intervention to improve spontaneous adverse reaction reporting by hospital physicians. A time series analysis in Spain. *Drug Saf* 2009;32:77-83.
- Pedrós Cholvi C, Arnau de Bolós JM. Interacciones farmacológicas en geriatría. *Rev Esp Geriatr Gerontol* 2008;43:261-3.
- Vallano A, Cereza G, Pedrós C, Agustí A, Danés I, Aguilera C, Arnau JM. Obstacles and solutions for spontaneous reporting of adverse drug reactions in the hospital. *Br J Clin Pharmacol* 2005;60:653-8.
- Cereza G, Pedrós C, García N, Laporte JR. Topiramate in non-approved indications and acute myopia or angle closure glaucoma. *Br J Clin Pharmacol* 2005;60:578-9.
- Pedrós C, Cereza G, García N. Hiponatremia y SIADH por inhibidores selectivos de la recaptación de serotonina: revisión de notificaciones espontáneas. *Med Clí (Barc)* 2004;123:516-7.
- Pedrós C, Cereza G, García N, Laporte JR. Hepatotoxicidad por extracto etanólico seco de *Camellia sinensis*. *Med Clí (Barc)* 2003;121:598-9.
- Castel JM, Figueras A, Pedrós C, Laporte JR, Capellà D. Stimulating adverse drug reaction reporting. Effect of a drug safety bulletin and of including yellow cards in prescription pads. *Drug Safety* 2003;26:1049-55.
- Figueras A, Pedrós C, Valsecia M, Laporte JR. Therapeutic ineffectiveness. Heads or tails? *Drug Safety* 2002;25:485-7.
- Capellà D, Pedrós C, Vidal X, Laporte JR. Case-population studies in pharmacoepidemiology. *Drug Safety* 2002;25:7-19.
- Castells X, Rodoreda I, Pedrós C, Cereza G, Laporte JR. Dysgeusia and burning mouth syndrome by eprosartan. *Br Med J* 2002;325:1277.
- Capellà D, Cereza G, Pedrós C. A propósito de los problemas relacionados con la medicación como causa del ingreso hospitalario. *Med Clí (Barc)* 2002;119:475.
- Pedrós C, Cereza G, Laporte JR. Primeras notificaciones espontáneas de sospechas de reacciones adversas a los nuevos antiinflamatorios selectivos sobre la ciclooxigenasa-2. *Med Clí (Barc)* 2002;118:415-7.
- Vallano Ferraz A, Pedrós Cholvi C, Montané Esteve E, Bejarano Romero F, López Andrés A, Cereza García G, Arnau de Bolós JM. Hemorragias en pacientes tratados con heparinas de bajo peso molecular. *Rev Clí Esp* 2002;202:583-7.
- Vallano A, Pedrós C. Asma inducida por ácido acetilsalicílico. *Med Clin (Barc)* 2001;117:274-5.
- Sarriá B, Pedrós C, Galán G, Cortijo J, Morcillo EJ. Effects of phorbol 12,13-diacetate on human isolated bronchus. *Eur J Pharmacol* 2000;399:65-73.
- Sabaté M, Bosch A, Pedrós C, Figueras A. Vitiligo associated with tolcapone and levodopa in a patient with Parkinson's disease. *Ann Pharmacother* 1999;33:1228-9.
- De Abajo F, Alvarez Requejo A, Ayani I, Carrillo JA, Carvajal A, Castillo JR, Cuchi T, Esteban Calvo C, Figueras A, García del Pozo J, González S, González Ruiz M, Herrero FT, Hidalgo A, Giménez Guillén C, Khalid H, Martínez MA, Madurga M, Martins MM, Mallén MM, de Diego IM, Martín-Serrano G, Montero D, Navarro M, Pedrós C, et al. Grupo de Investigación sobre la vacuna antimeningocócica del Sistema Español de Farmacovigilancia. Seguridad de la vacuna antimeningocócica A+C. Datos recogidos por el Sistema Español de Farmacovigilancia. *Gac Sanit* 1999;13:462-7.

Martínez Sánchez G, Pedrós C. Ácido épsilon aminocaproico e inhibición de la eyaculación. *Aten Primaria* 1998;22:63-4.

Vallano A, Aguilera C, Pedrós C, Juárez JR, Palomar M, Jodar R, Arnau JM, Laporte JR. Utilización de imipenem-cilastatina en un hospital universitario. *Farm Clin* 1994;11:572-6.

Cortijo J, Pedrós C, Ortiz JL, Morcillo E. Effects of cromakalim (BRL 34915) in trachea isolated from actively sensitized guinea pigs. *J Pharm Pharmacol* 1993;45:453-7.

Cortijo J, Sarriá B, Pedrós C, Perpiñá M, Paris F, Morcillo E. The relaxant effects of cromakalim (BRL 34915) on human isolated airway smooth muscle. *Naunyn Schmiedebergs Arch Pharmacol* 1992;346:462-8.

Projects

Principal investigator and coordinator on a multicentric study of risk of lactic acidosis associated with metformin use in patients with type 2 diabetes mellitus and chronic kidney disease funded by Institute of Health Carlos III.

Principal investigator and coordinator on a multicentric study of drug-induced nephrotoxicity funded by the Spanish Ministry of Health.

Principal investigator on several projects on epidemiology and monitoring of adverse drug reactions at hospital level; not funded.

Collaborator researcher on several projects related to adverse drug reaction, drug utilization and drug effectiveness funded by the Spanish Ministry of Health.

Memberships

President of the Committee for Safety of Medicinal Products for Human Use, Spanish Agency of Medicines and Medical Devices; since January 2025.

Vicepresident of the Committee for Safety of Medicinal Products for Human Use, Spanish Agency of Medicines and Medical Devices; February 2024-December 2025.

Member of the Pharmacotherapeutics Committee, Consorcio Hospital Universitario de Valencia; since January 2019.

Member of the Research Ethics Committee, Consorcio Hospital Universitario de Valencia; since January 2019.

Member of the Safety on Medicines Use Working Group, Catalan Institute of Health; June 2012-November 2018.

Member of the Clinical Safety Committee, Bellvitge University Hospital; May 2011-November 2018.

Assessor on scientific and technical evaluation of clinical research projects, Spanish Ministry of Health; 2010 and 2011.

Representative of the Clinical Pharmacology Service of the Bellvitge University Hospital in ENCePP (European Network of Centres for Pharmacoepidemiology and Pharmacovigilance); April 2008-November 2018.

Member of the Pharmacotherapeutics Committee, Bellvitge University Hospital; October 2007-November 2018.

Member of the Technical Committee of the Spanish Pharmacovigilance System; 1996-2007.

European Expert nominated by the Spanish Agency of Medicines and Medical Devices; since November 2005.

Member of the Spanish Society of Clinical Pharmacology; since 1994.

Other Relevant Information